Sobi pays $1.5bn for Arthrosi to grow in gout
Sobi has hit the acquisition trail with a deal to buy Arthrosi Therapeutics for up to $1.5 billion, adding a drug in late-stage clinical testing for gout. The deal, which includes a sizeable $950 million in upfront cash and $550 million tied to potential clinical, regulatory, and sales milestones, revolves around once-daily URAT1 inhibitor pozdeutinurad…